Mark Pruzanski, Intercept CEO (GlobeNewswire via YouTube)

September 1, 2020 05:14 PM EDT

Spurned by the FDA, Intercept brings out the budget axe and chops 170 jobs

John Carroll

Editor & Founder

The unexpected CRL that landed at Intercept Pharmaceuticals $ICPT 2 months ago is costing the biotech dearly.

In an SEC

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Revolution’s KRAS drugs appear competitive in several lung cancer settings

Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

FDA picks controversial doctor Vinay Prasad as CBER director, in about-face from Marks

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges